Fasciola hepatica extract suppresses fibroblast-like synoviocytes in vitro and alleviates experimental arthritis.
Suelen Pizzolatto DalmolinRenata Ternus PedóThales Hein da RosaJordana Miranda de Souza SilvaMirian FarinonMaria Luísa GaspariniEduardo Cremonese Filippi ChielaAna Helena PazMartín Pablo Cancela SehabiagueHenrique Bunselmeyer FerreiraRafaela Cavalheiro do Espírito SantoFabiany da Costa GonçalvesRicardo Machado XavierPublished in: Advances in rheumatology (London, England) (2022)
Our results point out a potential immunomodulatory effect of F. hepatica extract in RA models. Therefore, the characterization of promising new immunomodulatory molecules should be pursued, as they can promote the development of new therapies. Trial registration Collection of synovial liquid and in vitro procedures were approved by the Ethics Committee with Certificate of Presentation of Ethical Appreciation in Plataforma Brasil (CAAE: 89044918.8.0000.5327; date of registration: 26/07/2018).
Keyphrases
- rheumatoid arthritis
- oxidative stress
- public health
- anti inflammatory
- study protocol
- clinical trial
- signaling pathway
- phase iii
- ionic liquid
- phase ii
- big data
- case report
- mouse model
- randomized controlled trial
- human health
- decision making
- machine learning
- ankylosing spondylitis
- drug administration
- interstitial lung disease
- open label
- climate change
- systemic sclerosis
- deep learning